Recognise rapidly disseminating neuroendocrine lung cancer, stage thorax and brain promptly and coordinate time-sensitive chemoradiotherapy, systemic immunochemotherapy and paraneoplastic or supportive care.
Small-cell lung cancer is a poorly differentiated high-grade neuroendocrine cancer with near-universal disruption of TP53 and RB1. It usually arises centrally, producing cough, haemoptysis, recurrent collapse and bulky mediastinal nodes. Growth and dissemination are rapid, so constitutional symptoms, SVCO, liver or bone disease and brain metastases are frequent at diagnosis. Tissue may be fragile and crushed; specialist morphology and neuroendocrine immunohistochemistry must distinguish SCLC from other high-grade and well-differentiated tumours.
Staging is deliberately fast and decision-led. Contrast CT chest and upper abdomen establishes thoracic and common metastatic burden; brain MRI detects asymptomatic intracranial disease; PET-CT is most useful when limited-stage radical treatment is being planned or a finding needs resolution. TNM stage is recorded, but limited versus extensive stage remains clinically useful: limited disease can fit within a safe radical thoracic field, while extensive disease cannot. Bone marrow biopsy and indiscriminate tests are not routine when imaging already defines stage.
SCLC is strongly linked to cumulative cigarette exposure, with widespread genomic damage and only a small minority arising in never-smokers.
Pulmonary neuroendocrine epithelial cells acquire near-universal TP53 and RB1 loss with additional alterations driving rapid proliferation.
Radon, asbestos and other lung carcinogens may add risk, although the smoking association is stronger than for most cancers.
Some oncogene-driven adenocarcinomas transform histologically to SCLC under targeted-treatment pressure and require repeat tissue to identify the change.
Combined TP53 and RB1 dysfunction removes DNA-damage and retinoblastoma restraint, producing a very high growth fraction and early genomic instability.
SCLC infiltrates mediastinal nodes and blood vessels quickly, making occult distant and brain metastases common even with a modest primary.
Ectopic vasopressin or ACTH and paraneoplastic autoantibodies cause SIADH, Cushing syndrome and Lambert-Eaton neurological disease remotely.
Rapidly cycling cells often respond dramatically to platinum and radiation, but resistant subclones frequently cause early systemic relapse.
Cough, haemoptysis, breathlessness, lobar collapse and bulky mediastinal nodes are common because SCLC often arises near major bronchi.
Weeks of weight loss, fatigue, liver enlargement, bone pain or declining performance suggests early dissemination rather than a slowly localised tumour.
Facial and arm swelling, venous collaterals and positional head pressure from bulky mediastinal disease may require urgent stent or systemic treatment.
Euvolaemic hyponatraemia with concentrated urine can cause nausea, falls, confusion or seizure and needs severity-based correction.
Proximal leg weakness, dry mouth and reduced reflexes that facilitate after contraction supports a paraneoplastic presynaptic junction disorder.
Headache, focal deficit, seizure, gait change or cognitive decline requires urgent brain imaging and raised-pressure assessment.
High-grade neuroendocrine morphology overlaps, but cell size, architecture, necrosis and immunophenotype require specialist pathology and can alter evidence-based treatment.
Poorly differentiated squamous or adenocarcinoma can mimic SCLC on small crushed samples; adequate tissue and immunohistochemistry prevent misclassification.
Well-differentiated neuroendocrine tumours have lower proliferation, different morphology and a more indolent surgical and systemic pathway.
Small-cell morphology can arise in bladder, prostate, cervix and other sites, requiring imaging and pathology correlation to define origin.
Early haematogenous spread makes intracranial disease common, causing seizure, focal deficit, cognitive change and raised pressure that influences radiotherapy strategy.
Ectopic vasopressin causes water retention and hyponatraemia, producing confusion, falls, seizure and treatment delays if corrected unsafely.
Antibodies to presynaptic calcium channels cause leg-predominant weakness, autonomic symptoms and reduced reflexes that briefly facilitate after exercise.
Platinum-sensitive disease can later recur with resistant disseminated tumour, worsening performance and narrowing benefit from subsequent systemic treatment.
SCLC can progress visibly during a prolonged staging sequence, so each test should answer a decision about radical field, brain or systemic treatment.
It means known disease can fit a safe radical thoracic field, not simply that the primary appears small on one CT slice.
Adrenal deficiency, diuretics, renal failure and low solute intake can mimic the pattern and change treatment.
Intracranial-risk reduction must be balanced with cognition, age, MRI access, stage and the patient's view of surveillance and toxicity.
A dramatic early shrinkage does not guarantee cure because resistant subclones and occult dissemination make relapse common.
Allowing extensive serial investigation to delay time-sensitive treatment after adequate tissue and core staging.
Using limited stage as a synonym for any non-metastatic TNM stage without radiotherapy-volume assessment.
Calling hyponatraemia SIADH without serum and urine assessment and cortisol or medicine review.
Giving sequential treatment by default to a fit limited-stage patient who could tolerate early concurrent chemoradiotherapy.
Offering prophylactic cranial irradiation automatically without discussing MRI, cognition, age and preference.
Missing Lambert-Eaton syndrome or ectopic ACTH as treatable paraneoplastic causes of functional decline.
Continuing toxic relapse treatment without a predefined response and stopping threshold.
Your practice draft is saved in this browser.
A fit patient has confirmed limited-stage SCLC, adequate renal and pulmonary reserve and no brain metastasis. Which treatment approach offers the standard curative intent?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Extensive-stage disease is systemic from the outset. Platinum-etoposide combined with a funded checkpoint inhibitor is a common first-line approach, followed by immunotherapy maintenance in responders, while urgent radiotherapy treats brain, airway, bone or cord complications. At relapse, treatment depends on the treatment-free interval, prior toxicity, performance and current approvals; platinum-sensitive recurrence differs from early refractory growth. Palliative care is introduced early because symptom burden and decision tempo are high even when systemic response is substantial.
Use the exact NHS protocol and adjust for kidney, hearing, neuropathy and marrow reserve; prevent emesis and monitor febrile neutropenia, thrombosis, electrolyte wasting and tumour lysis.
Screen autoimmune, transplant, infection and organ context and educate about delayed immune lung, bowel, liver, endocrine, cardiac, renal, skin and neurological toxicity; hold and treat according to grade.
Myelosuppression and infection can be substantial in a pretreated patient; establish the response endpoint and stop early for refractory progression or unacceptable harm.